argenx SE (NASDAQ:ARGX) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. trimmed its position in argenx SE (NASDAQ:ARGX) by 10.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,412 shares of the company’s stock after selling 393 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in argenx were worth $1,829,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. TD Asset Management Inc lifted its holdings in argenx by 15.4% during the 1st quarter. TD Asset Management Inc now owns 223,695 shares of the company’s stock worth $88,073,000 after buying an additional 29,810 shares during the last quarter. Seven Eight Capital LP boosted its holdings in argenx by 66.4% in the first quarter. Seven Eight Capital LP now owns 3,110 shares of the company’s stock valued at $1,224,000 after purchasing an additional 1,241 shares in the last quarter. Clearbridge Investments LLC increased its stake in argenx by 36.5% in the first quarter. Clearbridge Investments LLC now owns 596,277 shares of the company’s stock valued at $234,766,000 after purchasing an additional 159,480 shares during the last quarter. FORA Capital LLC acquired a new stake in argenx during the first quarter worth approximately $2,024,000. Finally, Mediolanum International Funds Ltd acquired a new stake in argenx during the first quarter worth approximately $4,570,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on ARGX shares. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Truist Financial lifted their target price on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research report on Thursday. Barclays raised argenx from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, August 6th. Citigroup lifted their price target on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Finally, Wells Fargo & Company increased their price objective on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a report on Friday, July 26th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $557.11.

argenx Price Performance

ARGX opened at $586.30 on Friday. The business has a 50 day simple moving average of $536.55 and a 200-day simple moving average of $463.44. argenx SE has a 12 month low of $327.73 and a 12 month high of $589.60. The stock has a market capitalization of $34.84 billion, a P/E ratio of -102.37 and a beta of 0.63.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.